Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 146

Similar articles for PubMed (Select 19448557)

1.

Expanding antiretroviral options in resource-limited settings--a cost-effectiveness analysis.

Bendavid E, Wood R, Katzenstein DA, Bayoumi AM, Owens DK.

J Acquir Immune Defic Syndr. 2009 Sep 1;52(1):106-13. doi: 10.1097/QAI.0b013e3181a4f9c4.

2.

Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis.

Bendavid E, Grant P, Talbot A, Owens DK, Zolopa A.

AIDS. 2011 Jan 14;25(2):211-20. doi: 10.1097/QAD.0b013e328340fdf8.

3.

HIV drug resistance surveillance for prioritizing treatment in resource-limited settings.

Walensky RP, Weinstein MC, Yazdanpanah Y, Losina E, Mercincavage LM, Touré S, Divi N, Anglaret X, Goldie SJ, Freedberg KA; CEPAC International Investigators.

AIDS. 2007 May 11;21(8):973-82.

4.

Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.

Cruciani M, Mengoli C, Serpelloni G, Parisi SG, Malena M, Bosco O.

Cochrane Database Syst Rev. 2013 Jun 5;6:CD008270. doi: 10.1002/14651858.CD008270.pub2. Review.

PMID:
23740608
5.

Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy.

Freedberg KA, Kumarasamy N, Losina E, Cecelia AJ, Scott CA, Divi N, Flanigan TP, Lu Z, Weinstein MC, Wang B, Ganesh AK, Bender MA, Mayer KH, Walensky RP.

AIDS. 2007 Jul;21 Suppl 4:S117-28.

6.

Cost-effectiveness of the third-agent class in treatment-naive human immunodeficiency virus-infected patients in Portugal.

Aragão F, Vera J, Vaz Pinto I.

PLoS One. 2012;7(9):e44774. doi: 10.1371/journal.pone.0044774. Epub 2012 Sep 17.

7.

US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.

Brogan A, Mauskopf J, Talbird SE, Smets E.

Pharmacoeconomics. 2010;28 Suppl 1:129-46. doi: 10.2165/11587490-000000000-00000.

PMID:
21182348
8.

Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.

Moeremans K, Hemmett L, Hjelmgren J, Allegri G, Smets E.

Pharmacoeconomics. 2010;28 Suppl 1:147-67. doi: 10.2165/11587500-000000000-00000.

PMID:
21182349
9.

Economic evaluation of ART in resource-limited countries.

Loubiere S, Meiners C, Sloan C, Freedberg KA, Yazdanpanah Y.

Curr Opin HIV AIDS. 2010 May;5(3):225-31. doi: 10.1097/COH.0b013e3283384a9d. Review.

10.

Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy.

Humphreys EH, Chang LW, Harris J.

Cochrane Database Syst Rev. 2010 Jun 16;(6):CD006517. doi: 10.1002/14651858.CD006517.pub3. Review.

PMID:
20556768
11.

Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients.

Ruof J, Dusek A, DeSpirito M, Demasi RA.

Clin Drug Investig. 2007;27(7):469-79.

PMID:
17563127
12.

Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.

Brogan AJ, Talbird SE, Cohen C.

Value Health. 2011 Jul-Aug;14(5):657-64. doi: 10.1016/j.jval.2011.01.009. Epub 2011 Jun 12.

PMID:
21839403
13.

Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting.

Siripassorn K, Manosuthi W, Chottanapund S, Pakdee A, Sabaitae S, Prasithsirikul W, Tunthanathip P, Ruxrungtham K; Bamrasnaradura Study Team.

AIDS Res Hum Retroviruses. 2010 Feb;26(2):139-48. doi: 10.1089/aid.2009.0125.

PMID:
20156097
14.

Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial.

Cook J, Dasbach E, Coplan P, Markson L, Yin D, Meibohm A, Nguyen BY, Chodakewitz J, Mellors J.

AIDS Res Hum Retroviruses. 1999 Apr 10;15(6):499-508.

PMID:
10221527
15.

Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA.

Mauskopf J, Brogan A, Martin S, Smets E.

Pharmacoeconomics. 2010;28 Suppl 1:83-105. doi: 10.2165/11587470-000000000-00000.

PMID:
21182346
16.

Cost-effectiveness of point-of-care viral load monitoring of antiretroviral therapy in resource-limited settings: mathematical modelling study.

Estill J, Egger M, Blaser N, Vizcaya LS, Garone D, Wood R, Campbell J, Hallett TB, Keiser O; IeDEA Southern Africa.

AIDS. 2013 Jun 1;27(9):1483-92. doi: 10.1097/QAD.0b013e328360a4e5.

17.

Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.

Jaspan HB, Berrisford AE, Boulle AM.

Pediatr Infect Dis J. 2008 Nov;27(11):993-8. doi: 10.1097/INF.0b013e31817acf7b.

PMID:
18818556
18.

Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.

Moeremans K, Annemans L, Löthgren M, Allegri G, Wyffels V, Hemmet L, Caekelbergh K, Smets E.

Pharmacoeconomics. 2010;28 Suppl 1:107-28. doi: 10.2165/11587480-000000000-00000.

PMID:
21182347
19.

Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.

Pujades-Rodríguez M, O'Brien D, Humblet P, Calmy A.

AIDS. 2008 Jul 11;22(11):1305-12. doi: 10.1097/QAD.0b013e3282fa75b9.

PMID:
18580610
20.

Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis.

Bendavid E, Young SD, Katzenstein DA, Bayoumi AM, Sanders GD, Owens DK.

Arch Intern Med. 2008 Sep 22;168(17):1910-8. doi: 10.1001/archinternmed.2008.1.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk